Plain-English translation of NCT05642715 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a harm reduction strategy can help people living with HIV who smoke cigarettes reduce their risk of serious diseases like lung cancer and heart disease. All participants will get access to an online quit-smoking program called BecomeAnEX+ and be offered (a medication that helps reduce cravings). Half the group will also receive personalized counseling and support from a patient navigator focused on harm reduction—which means helping people quit if possible, but also helping those who continue smoking to reduce the damage cigarettes cause.
Most people with HIV who smoke don't quit, even with standard quit-smoking treatments. This trial is testing whether a harm reduction approach—one that supports both quitting and reducing smoking—might work better for this group and help protect their health in the long run.
You likely qualify if…
You likely don't qualify if…
You would start by completing a health screening (blood pressure and cholesterol check) and answering questions about your smoking history and health. For the first 3 months, everyone gets access to the online BecomeAnEX+ program and . After that, you'll be randomly assigned to one of two groups: one group receives extra personalized counseling and support from a patient navigator focused on harm reduction, while the other receives standard care. You'll complete follow-up health checks and questionnaires at 3, 6, and 9 months.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States